• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

    2/14/24 4:36:10 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email
    SC 13G/A 1 d751841dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)

     

     

    ALLOGENE THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    019770 10 6

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 019770 10 6    13G    Page 2 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Arie Belldegrun, M.D.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States of America and Israel

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     3,192,581 Shares (1)

       6  

     Shared Voting Power

     

     6,703,323 Shares (2)

       7  

     Sole Dispositive Power

     

     3,192,581 Shares (1)

       8  

     Shared Dispositive Power

     

     6,703,323 Shares (2)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     9,895,903 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     5.8% (3)

    12  

     Type of Reporting Person

     

     IN

     

    (1)

    Includes 2,847,489 shares of common stock issuable within 60 days of December 31, 2023 upon the exercise of stock options held by the Reporting Person and 142,150 shares issuable upon the settlement of Restricted Stock Units held by the Reporting Person that are releasable within 60 days of December 31, 2023.

    (2)

    Includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 195,039 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun and (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, except to the extent of any pecuniary interest therein.

    (3)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 3 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Bellco Legacy IV, LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     4,710,120 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     4,710,120 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,710,120 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     2.8% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 4 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Bellco Legacy LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     195,039 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     195,039 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     195,039 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     0.1% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 5 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Vida Ventures LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Nevada

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     1,798,163 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     1,798,163 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,798,163 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     1.1% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 6 of 9 Pages

     

    Item 1(a).

    Name of Issuer:

    Allogene Therapeutics, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    210 East Grand Avenue

    South San Francisco, CA 94080

     

    Item 2(a).

    Names of Persons Filing:

    Arie Belldegrun, M.D.

    Bellco Legacy IV LLC

    Bellco Legacy LLC

    Vida Ventures LLC

     

    Item 2(b).

    Address of Principal Business Office, or, if none, Residence:

    The address of Arie Belldegrun, M.D. is:

    10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067

    The address of Bellco Legacy IV LLC and Bellco Legacy LLC is:

    10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067

    The address of Vida Ventures LLC is:

    40 Broad Street, #201, Boston, MA 02109

     

    Item 2(c).

    Citizenship:

    Arie Belldegrun: USA and Israel

    Bellco Legacy IV LLC: Delaware

    Bellco Legacy LLC: Delaware

    Vida Ventures LLC: Nevada

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock

     

    Item 2(e).

    CUSIP No.:

    019770 10 6

     

    Item 3.

    Not Applicable.


    CUSIP No. 019770 10 6    13G    Page 7 of 9 Pages

     

    Item 4.

    Ownership

    The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover page to this Schedule 13G. Ownership is stated as of December 31, 2023. This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.

     

    Reporting Person

       Shares Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class(1)
     

    Arie Belldegrun

         3,192,581        3,192,581        6,703,323        3,192,581        6,703,323        9,895,903        5.8 % 

    Bellco Legacy IV, LLC

         4,710,120        0        4,710,120        0        4,710,120        4,710,120        2.8 % 

    Bellco Legacy LLC

         195,039        0        195,039        0        195,039        195,039        0.1 % 

    Vida Ventures LLC

         1,798,163        0        1,798,163        0        1,798,163        1,798,163        1.1 % 

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable


    CUSIP No. 019770 10 6    13G    Page 8 of 9 Pages

     

    Item 10.

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    /s/ Arie Belldegrun
    Arie Belldegrun, M.D.

     

    Bellco Legacy IV LLC
    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Manager

     

    Bellco Legacy LLC
    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Manager

    Vida Ventures LLC

    By: VV Manager LLC, its Manager

    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Senior Managing Director

     

    Get the next $ALLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLO

    DatePrice TargetRatingAnalyst
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/14/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    8/8/2024$13.00 → $11.00Outperform
    Oppenheimer
    5/31/2024$11.00Overweight
    Piper Sandler
    1/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    1/5/2024Buy → Neutral
    Guggenheim
    12/8/2023$7.00Buy
    Citigroup
    12/8/2023Buy
    Citigroup
    More analyst ratings